[Clinical trial of topifram].
D000208:Acute Disease; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D004338:Drug Combinations; D004361:Drug Tolerance; D004485:Eczema / Q000188:drug therapy; D005260:Female; D005601:Framycetin / Q000627:therapeutic use*; D005938:Glucocorticoids; D006801:Humans; D007223:Infant; D007642:Keratosis / Q000188:drug therapy; D008010:Lichen Planus / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010915:Pityriasis / Q000188:drug therapy; D011536:Prurigo / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D012393:Rosacea / Q000188:drug therapy; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D014449:Tyrothricin / Q000627:therapeutic use*
D000891:Anti-Infective Agents, Local; D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D014449:Tyrothricin; D005601:Framycetin
Essais cliniques du topifram.